754.87

0.24% 1.84

After Hours: 754.87

Regeneron Pharmaceuticals Inc (REGN)

Overview News Price History Option Chain Financials Why REGN Down? Discussions Forecast

Regeneron Pharmaceuticals Inc stock is traded at $754.87, with a volume of 536.75K. It is up +0.24% in the last 24 hours and down -19.09% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Previous Close:

$753.03

Open:

$756.72

24h Volume:

536.75K

Relative Volume:

0.77

Market Cap:

$82.75B

Revenue:

$13.85B

Net Income/Loss:

$4.65B

P/E Ratio:

21.53

EPS:

35.06

Net Cash Flow:

$3.32B

1W Performance:

+1.55%

1M Performance:

-19.09%

6M Performance:

-23.37%

1Y Performance:

-5.41%

1-Day Range:

$749.51

$762.16

1-Week Range:

$735.95

$762.16

52-Week Range:

$735.95

$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name

Regeneron Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(914) 847-7000

Address

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Employee

14,176

Twitter

@regeneron

Next Earnings Date

2024-10-31

Latest SEC Filings

REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Neutral
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-12-24	Initiated	Bernstein	Outperform
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-21-23	Reiterated	Oppenheimer	Perform
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-24-23	Upgrade	Jefferies	Hold → Buy
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line
Sep-09-22	Upgrade	Jefferies	Underperform → Hold
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-06-22	Initiated	Jefferies	Underperform
May-23-22	Initiated	SVB Leerink	Outperform
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-09-21	Resumed	Wells Fargo	Overweight
Dec-07-21	Resumed	Cowen	Market Perform
Dec-06-21	Initiated	Goldman	Buy
Nov-19-21	Resumed	BMO Capital Markets	Outperform
Nov-05-21	Downgrade	The Benchmark Company	Buy → Hold
Jun-29-21	Initiated	H.C. Wainwright	Buy
Jan-25-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-13-21	Upgrade	The Benchmark Company	Hold → Buy
Jan-08-21	Upgrade	Citigroup	Neutral → Buy
Oct-05-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-20-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-09-20	Upgrade	SunTrust	Hold → Buy
May-26-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-28-20	Downgrade	Citigroup	Buy → Neutral
Apr-17-20	Upgrade	The Benchmark Company	Hold → Buy
Apr-08-20	Initiated	The Benchmark Company	Hold
Mar-31-20	Initiated	Wolfe Research	Peer Perform
Feb-27-20	Initiated	Barclays	Overweight
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Feb-26-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-25-20	Upgrade	Jefferies	Hold → Buy
Feb-11-20	Upgrade	Argus	Hold → Buy
Dec-24-19	Initiated	Raymond James	Mkt Perform
Dec-16-19	Downgrade	Evercore ISI	Outperform → In-line
Dec-13-19	Upgrade	Credit Suisse	Neutral → Outperform
Nov-12-19	Initiated	SunTrust	Hold
Nov-07-19	Upgrade	Citigroup	Neutral → Buy
Oct-17-19	Resumed	BofA/Merrill	Neutral
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy

View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

Nov 27, 2024

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - Business Wire

Nov 27, 2024

Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy - Yahoo Finance

Nov 27, 2024

Cell And Gene Therapy Market Growth in Future Scope 2024-2031 | - openPR

Nov 27, 2024

Nov 26, 2024

Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock? - MSN

Nov 26, 2024

Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch

Nov 26, 2024

Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.

Nov 26, 2024

Fmr LLC Has $10.89 Billion Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Nov 26, 2024

Dai ichi Life Insurance Company Ltd Sells 2,383 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Nov 26, 2024

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Bank of Montreal Can - MarketBeat

Nov 26, 2024

The Manufacturers Life Insurance Company Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Nov 26, 2024

Cerity Partners LLC Acquires 2,423 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Nov 26, 2024

Nov 25, 2024

Sarcopenia Market on Track for Major Expansion by 2034, According to DelveInsight | Biophytis, MyMD Pharma, N12: Erasmus Medical Center, Erasmus Medical Center, Novartis, Regeneron Pharmaceuticals - The Globe and Mail

Nov 25, 2024

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Nov 25, 2024

The Law Offices of Frank R. Cruz Continues Investigation of - GlobeNewswire

Nov 25, 2024

Sarcopenia Market on Track for Major Expansion by 2034, - openPR

Nov 25, 2024

Loomis Sayles & Co. L P Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Nov 25, 2024

Do Options Traders Know Something About Regeneron (REGN) Stock We Don't? - Yahoo Finance

Nov 25, 2024

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Harvest Fund Management Co. Ltd - MarketBeat

Nov 25, 2024

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Daiwa Securities Group Inc. - MarketBeat

Nov 25, 2024

Regeneron Pharmaceuticals (MEX:REGN) Enterprise Value : MXN1,511,984 Mil (As of Nov. 25, 2024) - GuruFocus.com

Nov 25, 2024

Age-related Macular Degeneration (AMD) Drugs Market Top - openPR

Nov 25, 2024

Nov 24, 2024

Regeneron's fourth-quarter sales climb 29 percent, beating estimates - FirstWord Pharma

Nov 24, 2024

Swedbank AB Purchases 13,705 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Nov 24, 2024

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 24, 2024

Nov 23, 2024